Good health for every patient—that is Janssen's primary motivation. To that end, the company provides safe and effective medicines, services and support. This goal requires the smartest science, the most creative minds, and a willingness to collaborate at every stage – from the fragile beginnings straight through commercialization and patient education – with researchers, governments and patient organizations.

The company focuses its unique open-innovation model on several of the most life-altering disorders and complex medical challenges of our time, and it does this in 5 therapeutic domains. Each day, our dedicated personnel work to bring innovative solutions to the patients in shorter and shorter time frames. As a Credo-driven Johnson & Johnson company, our responsibility is to put the patient first.

The world-wide Pharmaceutical Group has one joint, global approach.

The Janssen 2020 strategy was designed after an in-depth analysis of the overall healthcare landscape, including the opportunities and challenges it presents. 

42-23776509.jpg

The strategy rests on 3 strategic pillars, and within each pillar there are a number of concrete objectives.  

  1. In coming years, the company will do everything in its power to ensure that all patients who need innovative medicines are also given access to them.
  2. Within the 5 therapeutic domains, the company selects a limited number of diseases to concentrate on. Alzheimer's disease and a number of cancers are included in these already established disease domains. Possible additional diseases are selected on the basis of the following criteria:
    a.       It must be a disease with a large, unfulfilled medical need;
    b.      Promising research in that field must already be under way or be in development;
    c.    Janssen must have the best expertise related to this disease available in-house.
  3. The company investigates how it can offer better therapies and treatments which can provide added value to society. The aim of the company is to evolve toward a completely integrated patient and health care solution.

In concrete terms, Janssen wants to:

  • Make use of diagnostics and biomarkers to develop personalized medicines which can increase the patients' response rates.
  • Offer integrated care solutions to improve the effectiveness of the care provided and to reduce the total cost to society.

Strategy of Janssen in Belgium

Janssen in Belgium has translated this global strategy locally, in Belgium. In our country, Janssen is a leader in Research & Development and is a trend-setter in manufacturing. Janssen implements a growth strategy whose goal is to remain number 1 in all of these areas and to be able to remain anchored in Belgium. 

 

In 2013, the local strategy, which is adapted along with our changing world, was revisited in a participatory process in which the employees helped to formulate a new vision. The vision process consists of ten steps, eight of which Janssen reviews in one year. In June of 2014, the entire process will be complete, and the strategy for the future will be worked out in detail and in line with our values—innovation, value creation, entrepreneurship, collaboration, open-mindedness and sustainability.

About
Janssen

Patient care is central to everything Janssen does. After more than fifty years, that is and remains the main reason we exist.

There is no time to waste in health care. The way in which we will make diagnoses, administer medication, identify or prevent diseases and monitor patients will be revolutionarily different from today. That is why Janssen is evolving from a pharmaceutical company into an organization offering total healthcare solutions tailored to individual patients.